These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26865640)

  • 1. Angiogenesis in melanoma: an update with a focus on current targeted therapies.
    Jour G; Ivan D; Aung PP
    J Clin Pathol; 2016 Jun; 69(6):472-83. PubMed ID: 26865640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
    Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis in malignant melanoma.
    Felcht M; Thomas M
    J Dtsch Dermatol Ges; 2015 Feb; 13(2):125-36. PubMed ID: 25631130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of angiogenesis inhibitors in the management of melanoma.
    Zaki KA; Basu B; Corrie P
    Curr Top Med Chem; 2012; 12(1):32-49. PubMed ID: 22196268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis in melanoma.
    Mahabeleshwar GH; Byzova TV
    Semin Oncol; 2007 Dec; 34(6):555-65. PubMed ID: 18083379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research progress in advanced melanoma.
    Luo C; Shen J
    Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathway ahead in melanoma trials.
    Miller AJ; Markovic SN; Haluska P
    Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.
    Pastushenko I; Vermeulen PB; Van den Eynden GG; Rutten A; Carapeto FJ; Dirix LY; Van Laere S
    Br J Dermatol; 2014 Aug; 171(2):220-33. PubMed ID: 24641095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.
    Schuster C; Akslen LA; Straume O
    PLoS One; 2016; 11(5):e0155242. PubMed ID: 27166673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatological aspects of angiogenesis.
    Velasco P; Lange-Asschenfeldt B
    Br J Dermatol; 2002 Nov; 147(5):841-52. PubMed ID: 12410692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
    Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
    Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and melanoma.
    Dutcher JP
    Curr Oncol Rep; 2001 Jul; 3(4):353-8. PubMed ID: 11389821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis in Dermatology - Insights of Molecular Mechanisms and Latest Developments.
    Richarz NA; Boada A; Carrascosa JM
    Actas Dermosifiliogr; 2017; 108(6):515-523. PubMed ID: 28162227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted therapy for melanoma: current reality and future options.
    Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
    Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in primary tumor cells of metastatic and nonmetastatic malignant melanoma.
    Mowlavi A; Malafa MP
    Plast Reconstr Surg; 2000 Aug; 106(2):514. PubMed ID: 10946963
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiogenesis and lymphangiogenesis of skin cancers.
    Dadras SS; Detmar M
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1059-70, viii. PubMed ID: 15474335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic and antiapoptotic treatment in advanced melanoma.
    Nikolaou V; Stratigos A; Bafaloukos D; Katsambas A
    Clin Dermatol; 2013; 31(3):257-63. PubMed ID: 23608445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
    Moschos SJ; Odoux C; Land SR; Agarwala S; Friedland D; Volker KM; Sidor C; Wong M; Kirkwood JM
    Melanoma Res; 2007 Jun; 17(3):193-200. PubMed ID: 17505265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.
    Singh S; Sadanandam A; Nannuru KC; Varney ML; Mayer-Ezell R; Bond R; Singh RK
    Clin Cancer Res; 2009 Apr; 15(7):2380-6. PubMed ID: 19293256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.